MACC1 INVOLVED IN THE REGULATION OF RESISTANCE OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE GASTRIC CANCER CELLS TO TRASTUZUMAB

被引:0
|
作者
Zhang, Guofei [1 ]
Hu, Kefu [1 ]
Yu, Rong [1 ]
Su, Gang [1 ]
Xiong, Xin [1 ]
Hu, Daqian [1 ]
Zhang, Zhihong [1 ]
机构
[1] Gongan Cty Peoples Hosp, Dept Oncol, Shizikou Town, Gongan County, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2019年 / 35卷 / 05期
关键词
MACC1; gene; human HER2-positive gastric cells; trastuzumab; resistance; POOR-PROGNOSIS; EXPRESSION; LONG;
D O I
10.19193/0393-6384_2019_5_381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We sought to analyze whether the mechanism of the MACC1 gene involved in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer cells regulates trastuzumab-resistant gastric cancer. Methods: Cell lines sensitive to trastuzumab and positive for MACC1 and HER2 expression were screened from human gastric cancer cell lines, drug-resistant cell MKN45/TR was established by a stepwise dose-increase method, and the expression level o f MACC1 protein in trastuzumab-resistant cells was detected using Western blot. The inhibition rate of cell proliferation after trastuzumab treatment for 72 hours was detected using MTT. Results: Drug-resistant cell MKN45/TR was established using a stepwise dose-increase method. Half-maximal inhibitory concentration and resistance index of cell trastuzumab were detected during the induction period .The induction time was five months and the final induction concentration was 2,500 mu g/mL. Additionally, the half-maximal inhibitory concentration of trastuzumab was 295.15 mu g/mL and the drug resistance index was 9.67. Western blot detection results showed that, as compared with cells without drug resistance, the MACC1 protein level of trastuzumab-resistant cells obviously increased. NCI-N87/TR and MKN45/TR were given transinfection using MACC1 interference and empty vector and were treated using different concentrations of trastuzumab. The cell inhibition rate was detected using the MTT method. Under the function of trastuzumab at concentrations of 20 mu g/mL, 80 mu g/mL, and 160 mu g/mL, there was statistical significance between the interference group and the control group with respect to the inhibition rate of cell proliferation (P<0.05). Conclusion: MACC1 participates in the regulation of trastuzumab in gastric cancer cells. The expression level of MACC1 protein cells in transinfection resistance increases, thus interfering MACC1 in resistance cells and reversing the resistance of MACC1.
引用
收藏
页码:2439 / 2443
页数:5
相关论文
共 50 条
  • [21] Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis
    Shen, Kai
    Ma, Xuelei
    Zhu, Chenjing
    Wu, Xin
    Jia, Hongyuan
    SCIENTIFIC REPORTS, 2016, 6
  • [22] Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Wolff, Antonio C.
    Tung, Nadine M.
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) : 2189 - +
  • [23] Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer
    Kim, Miriam
    Agarwal, Surbhi
    Tripathy, Debu
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2014, 26 (01) : 27 - 33
  • [24] Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer
    Eberst, Lauriane
    Bailleux, Caroline
    Bachelot, Thomas
    CURRENT OPINION IN ONCOLOGY, 2020, 32 (06) : 555 - 560
  • [25] Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Lee, Changro
    Park, Seho
    Kim, Joo Heung
    Lim, Sung Mook
    Park, Hyung Seok
    Kim, Seung Il
    Park, Byeong-Woo
    JOURNAL OF BREAST CANCER, 2016, 19 (04) : 385 - 393
  • [26] Risk Factors Associated with Trastuzumab-induced Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
    Abdel-Razaq, Wesam
    Alzahrani, Mohammed
    Al Yami, Majed
    Almugibl, Faisal
    Almotham, Mohammed
    Alregaibah, Razan
    JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2019, 11 (04): : 348 - 354
  • [27] Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients
    Fang, Yan
    Wang, Zheng
    Wu, Jiayi
    Huang, Ou
    He, Jianrong
    Zhu, Li
    Chen, Weiguo
    Li, Yafen
    Chen, Xiaosong
    Shen, Kunwei
    JOURNAL OF CANCER, 2020, 11 (09): : 2602 - 2609
  • [28] Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions
    Soleja, Mohsin
    Rimawi, Mothaffar F.
    CURRENT PROBLEMS IN CANCER, 2016, 40 (2-4) : 117 - 129
  • [29] Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer
    Lv, Huimin
    Yan, Min
    Jiang, Zefei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [30] 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer
    Ulaner, Gary A.
    Hyman, David M.
    Lyashchenko, Serge K.
    Lewis, Jason S.
    Carrasquillo, Jorge A.
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (12) : 912 - 917